🔴 Edesa Biotech is trading 5% down today amid broad-market sell-off and biotech weakness

Edesa Biotech is trading 5.24% lower at $2.53, in line with a sharp broader-market sell-off and weakness in biotech stocks.

• Major U.S. indexes are lower, while the XBI biotech ETF is down 2.06%; technology-led risk aversion and inflation concerns may weigh on sentiment.
• The FDA’s October 15 clearance for the EB06 vitiligo study was positive prior-day news, not a reported negative catalyst. U.S. enrollment is expected next quarter, with topline data anticipated in Q4 2027.